Lundbeck Reports Results Of ADAGIO Study With Azilect
Lundbeck’s partner Teva has announced that results from the ADAGIO trial, which demonstrated that Parkinson’s disease patients receiving Azilect (rasagiline) 1mg/day at the start of the study (early-start
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.